Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 2/20 | 0.40 |
| ▸ | PDE8B | O95263 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2896341 | 1.00 | HSD17B10 (0.45) | HSD17B10HPGDSMN1; SMN2EPHX1ALDH1A1 | |
| SCHEMBL1991179 | 1.00 | HSD17B10 (0.45) | HSD17B10HPGDSMN1; SMN2EPHX1ALDH1A1 | |
| SCHEMBL25980668 | 0.98 | HPGD (0.47) | HSD17B10HPGDSMN1; SMN2EPHX1ALDH1A1 | |
| SCHEMBL31336384 | 0.98 | HPGD (0.47) | HSD17B10HPGDSMN1; SMN2EPHX1ALDH1A1 | |
| SCHEMBL14398395 | 0.98 | HPGD (0.47) | HSD17B10HPGDSMN1; SMN2EPHX1ALDH1A1 | |
| SCHEMBL338312 | 0.95 | HSD17B10 (0.49) | HSD17B10HPGDSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL40804 | 0.95 | HSD17B10 (0.49) | HSD17B10HPGDSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL190173 | 0.95 | HSD17B10 (0.49) | HSD17B10HPGDSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL2030521 | 0.88 | HSD17B10 (0.41) | HSD17B10HPGDSMN1; SMN2EPHX1ALDH1A1 | |
| SCHEMBL17980096 | 0.88 | HSD17B10 (0.41) | HSD17B10HPGDSMN1; SMN2EPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124214-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2026-05-07 | — | — | US | disclosed |
| US-12617779-B2 | Self degradation-type CDK9 inhibitor prodrug and liposome encapsulating same | Sumitomo Pharma Co., Ltd. (JP) | 2026-05-05 | — | — | US | disclosed |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260103459-A1 | SUBSTITUTED AZACYLES AS TRPM8 MODULATORS | GIVAUDAN SA (CH) | 2026-04-16 | — | — | US | disclosed |
| EP-4709376-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | Blossomhill Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12528801-B2 | Substituted azacyles as TRPM8 modulators | GIVAUDAN SA (CH) | 2026-01-20 | — | — | US | disclosed |
| EP-4640279-A2 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2025-10-29 | — | — | EP | disclosed |
| EP-4356969-B1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2025-07-09 | — | — | EP | disclosed |
| EP-4192422-B1 | COOLING SENSATION COMPOSITIONS | GIVAUDAN SA (CH) | 2025-06-11 | — | — | EP | disclosed |
| US-6369078-B1 | Solenopsin derivatives and analogues as fire ant suppressants | BOWEN J PHILLIP (US) | 2002-04-09 | — | — | US | disclosed |
| US-5827860-A | Peptidyl heterocycles useful in the treatment of thrombin related disorders | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-10-27 | — | — | US | disclosed |
| US-5827866-A | ANTICOAGULANTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-10-27 | — | — | US | disclosed |
| CN-1192747-A | Peptidyl heterocyclic compounds for the treatment of thrombin-related diseases | ORTHO PHARMA CORP (US) | 1998-09-09 | — | — | CN | disclosed |
| WO-1998033793-A1 | α-AZACYCLOMETHYL BENZOTHIOPHENE AND α-AZACYCLOMETHYL BENZOFURANE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION | SANOFI-SYNTHELABO (FR) | 1998-08-06 | — | — | WO | disclosed |
| WO-1996040741-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040742-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATEDDISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040748-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5523308-A | SERINE PROTEASES INHIBITORS; ORAL ANTICOAGULANTS; CHEMICAL INTERMEDIATES; DIPEPTIDES | ORTHO PHARMACEUTICAL CORPORATION | 1996-06-04 | — | — | US | disclosed |
| WO-1991000724-A1 | ALKYNYL AMINES THAT REGULATE CHOLINERGIC NEUROTRANSMISSION | ABBOTT LABORATORIES (US) | 1991-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103459-A1 | SUBSTITUTED AZACYLES AS TRPM8 MODULATORS | TRPM8, TRPM7, TRPM5 | HSD17B10 3385/4885HPGD 3732/4885SMN1; SMN2 2680/4885 |
| US-12617779-B2 | Self degradation-type CDK9 inhibitor prodrug and liposome encapsulating same | CDK9, CDK6, CDK19 | HSD17B10 2254/4885HPGD 4009/4885SMN1; SMN2 2118/4885 |
| US-20260124214-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CBR1, NR3C1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HSD17B10 421/4885HPGD 1203/4885SMN1; SMN2 2272/4885 |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | HSD17B10 1332/4885HPGD 3581/4885SMN1; SMN2 4141/4885 |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | MDM2, TP53, XIAP | HSD17B10 2871/4885HPGD 2935/4885SMN1; SMN2 2441/4885 |
| US-12528801-B2 | Substituted azacyles as TRPM8 modulators | TRPM8, TRPM7, TRPM4 | HSD17B10 2254/4885HPGD 3427/4885SMN1; SMN2 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.